U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season

The FDA has approved Merck's ENFLONSIA (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants born during or entering their first RSV season. ENFLONSIA, a long-acting monoclonal antibody, demonstrated an 60.5% reduction in RSV-associated medically attended lower respiratory infections and an 84.3% reduction in RSV-associated hospitalizations in clinical trials. Merck anticipates ENFLONSIA will be available in the U.S. before the start of the 2025-2026 RSV season.

Analysis

Merck (MRK) has secured U.S. FDA approval for ENFLONSIA™ (clesrovimab-cfor), a novel long-acting monoclonal antibody designed for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season. This approval is particularly significant given RSV's status as a leading cause of infant hospitalization in the U.S. The decision is supported by compelling efficacy data from the pivotal Phase 2b/3 CLEVER trial, which demonstrated a 60.5% reduction in RSV-associated medically attended lower respiratory infections (MALRI) (p<0.001) and a notable 84.3% reduction in RSV-associated hospitalizations (p<0.001) compared to placebo over a typical 5-month RSV season. A key differentiating feature of ENFLONSIA is its convenient, non-weight-based 105 mg dosing, simplifying administration. The Phase 3 SMART trial further supported the approval, indicating comparable safety and extrapolated efficacy versus palivizumab in infants at increased risk for severe RSV. Merck plans for product availability ahead of the 2025-2026 RSV season, contingent upon anticipated recommendations from the CDC's Advisory Committee on Immunization Practices later this month, suggesting a near-term revenue opportunity. The safety profile was reported as generally comparable to placebo, with common adverse reactions being mild to moderate injection-site erythema, swelling, and rash.

Key Decisions for Investors

• Investors should view the FDA approval of ENFLONSIA as a significant positive development for Merck, likely strengthening its pediatric franchise and offering a new revenue stream in the substantial RSV prevention market.
• Closely monitor the forthcoming recommendations from the CDC's Advisory Committee on Immunization Practices and the subsequent commercial launch and market uptake of ENFLONSIA during the 2025-2026 RSV season to gauge its competitive positioning and initial sales trajectory.
• Consider the potential for ENFLONSIA's unique non-weight-based dosing regimen to drive market share capture and re-evaluate Merck's growth prospects based on the successful introduction of this high-efficacy product.
• Factor in the potential impact of ENFLONSIA on Merck's financial forecasts, particularly concerning its ability to address the significant burden of RSV on healthcare systems and families.